Not yet recruitingRare disease

A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura.

Verified siteInvestigationalNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on diseases known as Thrombotic Microangiopathies, a group of conditions where small blood vessels become damaged and blocked by tiny blood clots. One specific type of this condition is Immune-Mediated Thrombocytopenic Purpura, a rare disorder where the body's immune system mistakenly attacks and destroys platelets, which are the cells responsible for helping blood clot. The research aims to evaluate the safety and effectiveness of an experimental drug called TGD001. This medication is a specialized protein designed to target certain factors in the blood that contribute to the formation of these harmful clots.

The treatment involving TGD001 is administered through an intravenous method, which means it is delivered directly into a vein using a solution for injection. During the study, participants will receive the medication to observe how the body reacts and to see if it helps manage the symptoms of the disease. The process involves monitoring how the drug moves through the body and checking for any side effects or changes in blood cell levels over time.

The research process

The trial runs in 2 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Administration of study medication
An intravenous injection of tgd001 is administered. tgd001 is a test medication consisting of urokinase, catalytic domain, fused with a single-chain antibody against von willebrand factor, provided as a solution for injection.
This medication is intended to treat conditions such as immune-mediated thrombotic thrombocytopenic purpura (iTTP) or other thrombotic microangiopathies, which are disorders involving blood clotting issues.
Step 2
Monitoring and assessment
The safety and tolerability of the medication are monitored throughout the process.
Assessments are conducted to track the time to clinical response and changes in platelet count, which refers to the number of cells in the blood that help with clotting.
The time taken for platelets to return to a level of 150×10E9/L or higher is measured.
Changes in organ damage markers and the time required for ldh (a type of enzyme measured in the blood) to return to a normal range are recorded.
The signs and symptoms of the disease are evaluated for improvement within 90 days after the medication is given.
The duration of any hospitalization or time spent in the intensive care unit is tracked.
plasma concentrations of the medication and how the body processes it are measured.
The development of ada, which are antibodies produced by the body against the medication, is monitored.

Who can join the trial?

5 criteria

You must be an adult, which means you are 18 years of age or older when you sign the study agreement.
You must be willing and able to understand the study details and sign the informed consent form, which is a document that explains everything about the study before you agree to join.
If you are a man or a woman who could become pregnant, you must avoid sexual intercourse or use a highly effective method of birth control (one that has a failure rate of less than 1% per year) during the study and for at least 90 days after your last dose of the study medicine.
You must be experiencing symptoms of an acute TMA episode, which is a sudden and serious condition involving thrombotic microangiopathy, a medical issue where small blood clots form in tiny blood vessels throughout the body.
You must be able to attend all necessary follow-up appointments to monitor your health during the study.

Who cannot join the trial?

13 criteria

Having a different medical condition that explains low blood platelets or hemolytic anemia (a condition where red blood cells are destroyed more quickly than normal) instead of thrombotic microangiopathy (a group of disorders that cause blood clots in small blood vessels).
Having other serious medical, brain-related, or mental health conditions that might make it difficult for doctors to accurately measure the study results.
Having a known hypersensitivity (an allergic reaction) to the study drugs, any of the ingredients used to make them, or drugs that are very similar to them.
Having taken part in another study involving an experimental drug or medical device within the last 30 days that could interfere with this study.
Being unable to follow the specific rules and steps required for this study.
Having a severe, active infection known as sepsis (a life-threatening reaction to an infection that requires medicine to help raise blood pressure).
Being pregnant or currently breastfeeding.
A history of bleeding diathesis (a tendency to bleed more easily or for a longer time than normal) or showing signs of unusual bleeding in the last 30 days.
Having active bleeding inside the body.
Showing signs of symptomatic intracranial hemorrhage (bleeding inside the skull that causes symptoms like headache or confusion).
Having very high, uncontrolled hypertension (high blood pressure), defined as a top number higher than 180 or a bottom number higher than 110.
Having cancer that has spread throughout the body or other serious illnesses that would limit life expectancy to less than 3 months.
Having had a major surgery recently, as decided by the study doctor.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Assistance Publique Hopitaux De Paris
Verified
Paris, France
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Verified
Milan, Italy
Hospital Universitario Y Politecnico La Fe
Verified
Valencia, Spain

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

TGD001 is a medication being tested to see if it is safe and effective for people with certain blood disorders. It works by targeting the processes in the body that cause abnormal blood clots to form in small blood vessels.

UROKINASE, CATALYTIC DOMAIN, FUSED WITH A SINGLE-CHAIN ANTIBODY AGAINST VON WILLEBRAND FACTOR

What is already known about the treatment

Urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor - This experimental medication is administered as a solution through an intravenous injection into the bloodstream. Currently being studied in clinical trials, it is being investigated for its potential to treat rare blood disorders like immune-mediated thrombotic thrombocytopenic purpura and other conditions where small blood clots form in vessels. This drug works by using a specific antibody to target and bind to von Willebrand factor, a protein that helps blood clot, while the urokinase part helps break down existing clots. It is classified as a targeted enzyme-based therapy designed to prevent and dissolve harmful blood clotting.

Investigated diseases

Immune-Mediated Thrombotic Thrombocytopenic Purpura
This is a rare blood disorder where the body's immune system mistakenly attacks an enzyme needed to break down blood clots. This process leads to the formation of small blood clots throughout the body's blood vessels. As these clots form, they consume a large number of platelets, which are the cells responsible for clotting. This results in a significant decrease in the overall platelet count in the bloodstream. The condition typically progresses through the rapid development of these micro-clots and a subsequent drop in platelets.
Thrombotic microangiopathy
This term describes a group of conditions characterized by the formation of tiny blood clots within small blood vessels. These small clots can obstruct blood flow and cause damage to various tissues and organs. The condition involves a decrease in platelet counts and the presence of damaged red blood cells in the blood. It can progress by affecting different organ systems depending on where the vessel blockage occurs. The underlying mechanism involves various ways the body's clotting and blood cell processes are disrupted.